Abstract 2057P
Background
Aging-related deficits that eventually manifest as frailty are emerging as an important determinant for quality of life and emotional health in older patients with cancer. Prevalence of frailty in long-term prostate cancer survivors and its impact on quality of life have not been investigated so far. The objective of the current study was (I) to assess the prevalence of frailty and (II) to elucidate the relationship between frailty, quality of life and emotional health in long-term prostate cancer survivors after radical prostatectomy.
Methods
2979 prostate cancer survivors from the multicenter German Familial Prostate Cancer Database were included. Patients completed the following standardized patient-reported outcome measures of interest: frailty (Groningen Frailty Indicator, GFI), quality of life (EORTC QL2), and emotional health (anxiety/depression symptoms, PHQ-4). Chi-square tests and Wilcoxon-Mann-Whitney tests were used to detect differences of selected variables between frail and non-frail patients. Associations were assessed using multiple linear regression analysis.
Results
The patients’ mean age was 79.4 years (SD = 6.4) and mean time since radical prostatectomy was 17.4 years (SD = 3.8). 33.1% (985/2979) of patients were classified as frail (GFI ≥4). Regarding mental health and quality of life, frail patients reported more often symptoms of depression (24.0% vs. 4.0%; p<0.001) and anxiety (20.6% vs. 2.0%; p<0.001) as well as lower quality of life (M = 53.4 (SD = 19.2) vs. M = 72.7 (SD = 16.0); p<0.001) compared to non-frail patients. Frailty was significantly associated with depression (OR 1.68; CI 1.49-1.89), anxiety (OR 1.75; CI 1.55-1.97), lower quality of life (OR 0.72; CI 0.67-0.77), higher age (OR 1.04; CI 1.03-1.07), and a missing partnership (OR 1.83; CI 1.37-2.45).
Conclusions
Every third long-term prostate cancer survivor after radical prostatectomy was frail. The associations with lower quality of life and poorer mental health indicates the need for an integrated care approach including further geriatric assessment and possible interventions to improve health outcomes of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06